^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    samuraciclib (CT7001)

    i
    Company:
    Carrick Therap
    Drug class:
    CDK7 inhibitor
    Related drugs:
    Apply
    A Study of Samuraciclib in Combination With Fulvestrant in Metastatic or Locally Advanced Breast Cancer in Adult Participants (SUMIT-BC) (NCT05963984)
    Phase 2
    Carrick Therapeutics Limited
    Active, not recruiting
    Last update posted :
    02/21/2025
    Initiation :
    12/14/2023
    Primary completion :
    06/30/2025
    Completion :
    12/31/2025
    HER-2 • ER • TP53 • CDK4
    |
    TP53 mutation • ER positive • HER-2 negative • HER-2 negative + ER positive
    |
    fulvestrant • samuraciclib (CT7001)
    A Study of Samuraciclib and Elacestrant in Participants with Metastatic or Locally Advanced HR+/HER2-negative Breast Cancer (SUMIT-ELA) (NCT05963997)
    Phase 1/2
    Carrick Therapeutics Limited
    Active, not recruiting
    Last update posted :
    02/21/2025
    Initiation :
    10/09/2023
    Primary completion :
    12/23/2025
    Completion :
    12/23/2025
    HER-2 • ER • TP53 • CDK4
    |
    TP53 mutation • ER positive • HER-2 negative • HER-2 negative + ER positive • HER-2 negative + ER positive + ESR1 mutation
    |
    Orserdu (elacestrant) • samuraciclib (CT7001)
    A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer (MORPHEUS BC) (NCT04802759)
    Phase 1/2
    Hoffmann-La Roche
    Recruiting
    Last update posted :
    02/17/2025
    Initiation :
    06/22/2021
    Primary completion :
    11/30/2027
    Completion :
    11/30/2027
    ER • CDK4
    |
    HER-2 positive • ER positive
    |
    Herceptin (trastuzumab) • Tecentriq (atezolizumab) • Ibrance (palbociclib) • everolimus • Verzenio (abemaciclib) • Kisqali (ribociclib) • ipatasertib (RG7440) • Itovebi (inavolisib) • giredestrant (GDC-9545) • Pegasys (pegylated interferon α -2a) • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf) • samuraciclib (CT7001)
    Modular Study to Evaluate CT7001 Alone in Cancer Patients With Advanced Malignancies (CT7001_001) (NCT03363893)
    Phase 1/2
    Carrick Therapeutics Limited
    Completed
    Last update posted :
    12/22/2023
    Initiation :
    11/14/2017
    Primary completion :
    12/15/2022
    Completion :
    12/15/2022
    HER-2 • ER
    |
    fulvestrant • samuraciclib (CT7001)